Cero Therapeutics doses second patient in Phase 1 CER-1236 trial

CERo Therapeutics (CERO) announces it has dosed the second patient in the first cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid leukemia, AML. The patient was dosed at the Sarah Cannon Research Institute, SCRI, at Colorado Blood Cancer Institute, CBCI, in Denver, Colorado, with Yazan Migdady, M.D., an associate member physician at CBCI acting as principal investigator for the study. With more than seven days passed following the second patient’s infusion, monitoring continues for key safety, tolerability, and efficacy endpoints.